Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy | Zendy

Thomas Hank | Zendy; Marta Sandini | Zendy; Cristina R. Ferrone | Zendy; Clifton Rodrigues | Zendy; Maximilian Weniger | Zendy; Motaz Qadan | Zendy; Andrew L. Warshaw | Zendy; Keith D. Lillemoe | Zendy; Carlos Fernández-del Castillo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy

Author(s) -

Thomas Hank,

Marta Sandini,

Cristina R. Ferrone,

Clifton Rodrigues,

Maximilian Weniger,

Motaz Qadan,

Andrew L. Warshaw,

Keith D. Lillemoe,

Carlos Fernández-del Castillo

Publication year - 2019

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2019.2272

Subject(s) - medicine , pancreatic fistula , pancreatectomy , interquartile range , pancreatic cancer , proportional hazards model , neoadjuvant therapy , pancreaticoduodenectomy , univariate analysis , retrospective cohort study , surgery , gastroenterology , adenocarcinoma , multivariate analysis , pancreas , cancer , breast cancer

In the past decade, the use of neoadjuvant therapy (NAT) has increased for patients with borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Data on pancreatic fistula and related overall survival (OS) in this setting are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research